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Summary One hundred and forty-two patients with Hodgkin's disease PS I or II were treated with total or
subtotal nodal irradiation as part of a prospective randomized trial in the Danish National Hodgkin Study
during the period 1971-83. They were followed till death or - at the time of this analysis - from 15 to 146
months after initiation of therapy. The initial tumour burden of each patient was assessed, combining tumour
size of each involved region and number of regions involved. Tumour burden thus assessed proved to be the
single most important prognostic factor with regard to disease free survival. Other known prognostic factors
such as number of involved regions, mediastinal size, pathological stage, systemic symptoms, and ESR were
related to tumour burden and lost their prognostic significance in a multivariate analysis. The only other
factors of independent significance were histologic subtype and, to a lesser extent, sex. Combining tumour
burden and histologic subtype made it possible to single out a group of patients with a very poor disease free
survival. These patients also had a poorer survival from Hodgkin's disease and are thus clearly candidates for
additional initial treatment.
In early stage Hodgkin's disease several factors have been
shown to influence disease free survival after radiotherapy,
most notably bulky intrathoracic disease, number of regions
involved, stage, B-symptoms, ESR, histologic subtype, and
sex. Most of these factors are likely to be related to the
patient's total tumour burden. The patient's actual tumour
burden, however, does not come out in the Ann Arbor
staging system, since for the early stages this only
distinguishes between one or several involved regions. It does
not take tumour size into account, and lumps together quite
large areas as one region, e.g. either side of the neck and the
ipsilateral supraclavicular region.
The results of a recent smaller study seem to indicate that
for the early stages of Hodgkin's disease a large tumour
burden singles out patients destined to relapse after
treatment with radiotherapy alone more accurately than
other known prognostic factors (Specht & Nissen, 1986). In
the present article the prognostic significance of tumour
burden and its relation to other known prognostic factors is
examined in the total number of early stage patients who
after randomization were treated with radiotherapy alone in
the prospective Danish National Hodgkin Study (see below).
Patients and methods
Since 1971 all newly diagnosed previously untreated patients
with Hodgkin's disease in Denmark have been centrally
registered by the Danish National Hodgkin Study (LYGRA)
and subjected to uniform staging procedures (conforming to
the Ann Arbor classification (Carbone et al., 1971)) and
treatments. The diagnostic biopsies from all patients were
reviewed by a panel of pathologists and classified in
accordance with the method of Lukes and Butler (1966). All
patients in clinical stage I or II with supradiaphragmatic
presentation had an exploratory laparotomy with
splenectomy as part of the staging procedure, unless
medically contraindicated. From 1971 through 1983 all
previously untreated patients with supradiaphragmatic
Hodgkin's disease PS I and II (as confirmed by laparotomy)
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were entered in a prospective study and randomized to
receive either radiotherapy alone or radiotherapy plus
adjuvant combination chemotherapy (Nissen & Nordentoft,
1982). The 142 patients in the Danish National Hodgkin
Study who received radiotherapy only and who had no intial
extranodal manifestations form the study population.
Before radiotherapy was started all the involved peripheral
lymph nodes of each of the 142 patients were measured and
recorded. For the purpose of the present study the following
method of assessment of tumour burden was developed.
Uninvolved nodal sites were recorded as grade 1. To obtain
nodal sites of roughly equal size each side of the neck was
divided into 3 sites: upper neck, lower neck, and supra-
clavicular region. For each site the cumulated size of
involved lymph nodes was graded as follows: grade 2: largest
diameter .2cm, grade 3: 2cm< largest diameter .5cm,
grade 4: largest diameter >5cm. This grading scale was
developed to obtain a roughly equal distribution of involved
sites in the 3 grades. Out of a total of 255 involved sites 82
were grade 2, 101 were grade 3, and 72 were grade 4.
Mediastinal and hilar involvement was evaluated on the
basis of A-P and lateral chest radiographs. Involved
mediastini were graded from A-P chest films as follows:
grade 2: mediastinal index (i.e. maximum width of
mediastinum/maximum intrathoracic cage width) .0.25,
grade 3: 0.25< mediastinal index .0.33, grade 4:
mediastinal index >0.33. This commonly employed method
of grading mediastinal involvement gave the following
distribution of the 54 involved mediastini in this study: 11
grade 2, 30 grade 3, and 13 grade 4. Involved hili were
graded as follows: grade 2: largest diameter .5cm, grade 3:
5cm< largest diameter _7cm, grade 4: largest diameter
>7cm. This grading scale was developed in order to obtain
a roughly equal distribution of involved hili in the 3 grades.
Out of a total of 17 involved hili 3 were grade 2, 8 were
grade 3, and 6 were grade 4. The total tumour burden of
each patient was estimated by adding together the grades of
all the involved sites of that particular patient. Bilateral
involvement of mediastinum was considered as involvement
of 2 regions, and the grades of involved mediastini were
therefore multiplied by 2 before being added. Finally, the
patients were divided into groups based on tumour burden.
A division was made between patients with tumour burdens
<10 and patients with tumour burdens .10 based on the
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findings of the previous study (Specht & Nissen, 1986).
These 2 groups were further split into 2 subgroups, each
containing roughly half the patients of the original group.
The resulting 4 groups were defined as follows: group 1:
tumour burden <5, group 2: 5. tumour burden <10,
group 3: 10. tumour burden <15, and group 4: tumour
burden 15.
For each patient the following additional information was
registered: pathological stage and number of regions
involved (conforming to the Ann Arbor classification),
histologic subtype, pretreatment ESR, age, and sex.
All 142 patients received mantle field irradiation to a total
average dose of 36Gy (range 31 to 40Gy). Sixty-five patients
received additional irradiation to an inverted Y field to a
total average dose of 36Gy (range 29 to 40Gy), whereas the
remaining 77 patients received additional irradiation to a
para-aortic field to a total dose of 37Gy. All patients
entered complete remission except 3 who only attained
partial remission. 39/142 (28%) have relapsed so far. The
patients were followed until death or from 15 to 146 months
after initiation of therapy (median follow-up time 91
months).
Survival curves (from time of initiation of therapy) were
calculated according to the method of Kaplan and Meier
(1958), comparisons in univariate analyses were performed
by the logrank test (Peto et al., 1977). To determine the
independent contribution of each factor to prognosis a
multivariate analysis using the model developed by Cox was
used (Cox, 1972).
Results
Tumour burden for all 142 patients is shown in Table I in
relation to pathological stage, number of sites involved,
mediastinal size, histologic subtype, ESR, age, and sex. From
the table it is apparent that many of these prognostic factors
are related.
Table II shows the prognostic factors examined with
respect to disease free survival in the multivariate analysis:
tumour burden, number of involved regions, ESR (divided at
the value of 40, which gives the best separation with respect
to prognosis), pathological stage, histologic subtype, a
combination of systemic symptoms and ESR (reported by
Tubiana et al. (1985) to be of major prognostic significance
in CS I and II), mediastinal size, sex, and age. The last 3
factors were not significant with respect to disease free
survival in univariate analyses, whereas the rest were. In
Table I Relation between tumour burden (t.b., see Patients and methods) and patho-
logical stage (PS), number of regions involved (Ann Arbor classification), mediastinal
size, histologic subtype, ESR, age, and sex in 142 patients with Hodgkin's disease PS I or
II treated with radiotherapy alone. Number who relapsed in parentheses
t.b. <5 S_t.b. < 10 10 J t.b.< 15 15_t.b.
PS IA 46(6) 11(4) 2(0) 0
PS IB 4(2) 4(0) 0 0
PS IIA 1(0) 28(6) 18(6) 9(5)
PS IIB 0 4(0) 6(4) 9(6)
1 region 50(8) 15(4) 2(0) 0
2 regions 1(0) 28(6) 15(6) 0
3 regions 0 4(0) 9(4) 1(0)
4+ regions 0 0 0 17(11)
-mediastinal involv. 50(8) 28(8) 7(2) 3(2)
Grade 2 mediastinum 1(0) 7(1) 2(1) 1(0)
Grade 3 mediastinum 0 11(1) 11(7) 8(5)
Grade 4 mediastinum 0 1(0) 6(0) 6(4)
LP 13(0) 12(3) 5(0) 0
NS 22(4) 24(2) 15(7) 17(10)
MC 16(4) 11(5) 6(3) 1(1)
ESR<40 45(5) 34(8) 18(6) 5(3)
ESR_40 6(3) 13(2) 8(4) 13(8)
<40 years 32(7) 33(9) 21(7) 16(10)
.40 years 19(1) 14(1) 5(3) 2(1)
male 38(6) 24(9) 14(5) 12(9)
female 13(2) 23(1) 12(5) 6(2)
Table II Prognostic factors analysed by multivariate analysis in 142 patients with
Hodgkin's disease PS I or II treated with radiotherapy
Factor Coding
Tumour burden (see Patients and methods) 1 =0-4, 2=5-9, 3= 10-14, 4= > 15
No. involved regions 1= 1, 2=2, 3 =3, 4=4+
ESR 1= <40, 2=>40
PS 1=IA, 2=IB, 3=IIA, 4=IIB
Histologic subtype NS: 1=NS, 0=not NS
MC: 1=MC, 0=not MC
Systemic symptoms+ESR 1 =(A +ESR<50) or (B +ESR<30)
2=(A+ ESR>50) or (B+ESR>30)
Mediastinum (grading see Patients and methods) 0 = -, 1 =small, 2=medium, 3=large
Sex 1 =male, 2 =female
Age 1= <40, 2= _40TUMOUR BURDEN IN HODGKIN'S DISEASE 537
Table II is also shown the coding used in the multivariate
analysis. As there is no natural order of the histologic
subtypes this factor was split into 2 variables, 1 comparing
NS with LP and I comparing MC with LP.
All the recorded factors were included in the multivariate
analysis initially, and a step-down procedure was adopted,
dropping the least significant factor, and repeating the
analysis until only those factors with significant prognostic
influence (i.e., at 0.05 level) were left. The result regarding
disease free survival is shown in Table III. Only tumour
burden, histologic subtype, and sex turned out to be of
independent prognostic significance. Number of involved
regions, ESR, pathological stage, the combination of
systemic symptoms and ESR, and mediastinal size were all
closely correlated with tumour burden, offering no
independent prognostic information.
Tumour burden emerged clearly as the single most
important prognostic factor with regard to disease free
survival (P=0.0002). Disease free survival curves according
to tumour burden are shown in Figure 1. The second most
important factor was histologic subtype (P=0.0171). To
single out patients with a poor disease free survival in a
simple way these 2 factors were combined. Sex was not
included in the combination for the sake of simplicity, and
because it was only of marginal significance in multivariate
analysis and insignificant in univariate analysis. In Table I in
the section showing tumour burden vs. histologic subtype a
line has been drawn splitting the section in two. Above and
to the left of the line are 92 patients with a relatively low
relapse rate (corresponding to subgroups with estimated (from
the multivariate model) 5-year disease free survival over
0.75, slightly lower for men than for women), below and to
the right of the line are 50 patients with a relatively high
relapse rate (corresponding to subgroups with estimated 5-
year disease free survival less than 0.75, slightly lower for
men than for women). If this division in a good prognosis
group and a poor prognosis group, based on tumour burden
and histologic subtype, is applied, a highly significant
difference in disease free survival ensues (P<0.0000007,
Figure 2). In both groups men have a slightly poorer disease
free survival than women but in neither group does the
difference reach statistical significance (P=0.0798 and
P =0.1799 respectively). The difference in disease free
survival between the 2 groups translates into a significant
difference in survival from Hodgkin's disease (P=0.0025,
Figure 3), whereas the difference in overall survival
(including all causes of death) does not quite reach statistical
significance (P=0.0579).
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Figure 2 Disease free survival according to prognostic grouping
defined on the basis of tumour burden and histologic subtype in
142 patients with Hodgkin's disease PS I or II treated with
radiotherapy.
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Figure 1 Disease free survival according to tumour burden (t.b.)
in 142 patients with Hodgkin's disease PS I or II treated with
radiotherapy.
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Figure 3 Survival from Hodgkin's disease according to
prognostic grouping defined on the basis of tumour burden and
histologic subtype in 142 patients with Hodgkin's disease PS I or
II treated with radiotherapy.
Table III Coefficients of significant prognostic factors derived from Cox analysis of disease
free survival in 142 patients with Hodgkin's disease PS I or II treated with radiotherapy
Factor SE(f4) p Adversefeature
Tumour burden
(see Patients and methods) 0.62 0.17 0.0002 increasing tumour burden
NS 1.16 0.64 0.0171 NS as opposed to LP
MC 1.77 0.64J MC as opposed to LP
Sex -0.83 0.37 0.0248 male as opposed to female sex
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Discussion
The results of the present study confirm the findings of the
above mentioned smaller-scale study (Specht & Nissen, 1986)
to the effect that tumour burden is highly important, indeed
probably the most important prognostic factor for patients
in the early stages of Hodgkin's disease with regard to
disease free survival after treatment with radiotherapy only.
The concept of tumour burden combines the tumour size
of each involved region with the number of involved regions.
The number of involved regions has been shown by other
studies to be of major prognostic significance (Tubiana et
al., 1985; Liew et al., 1984; Thar et al., 1979; Leslie et al.,
1985). As demonstrated above, however, tumour burden
offers some extra prognostic information. This is in
accordance with the findings that local control by
radiotherapy is poorer for large than for small tumours
(Thar et al., 1979), and that the presence of a large mass of
lymph nodes adversely affects disease free survival after
radiotherapy (Anderson et al., 1984).
ESR has also been shown to be of major prognostic
significance with regard to disease free survival (Tubiana et
al., 1985; Haybittle et al., 1985). Both of these studies,
however, comprised both clinically and pathologically staged
patients. In the present study ESR is clearly related to
tumour burden and does not give significant independent
prognostic information. Combining ESR with systemic
symptoms as proposed by Tubiana et al. (1985) does not
alter this.
Pathological stage is closely related to tumour burden and
has no independent prognostic significance.
Mediastinal involvement, particularly bulky mediastinal
involvement, has in many studies been shown to adversely
influence disease free survival after radiotherapy (Nissen &
Nordentoft, 1982; Liew et al., 1984; Thar et al., 1979; Leslie
et al., 1985; Dorreen et al., 1984; Hoppe et al., 1982; Lee et
al., 1980; Schomberg et al., 1984; Mauch et al., 1982). In
most earlier studies it has, however, not been taken into
account that mediastinal involvement is rare in stage I
whereas it is very common in stage II. Thus, in a recent
study (Haybittle et al., 1985) it was found that clinical stage
and mediastinal involvement gave similar prognostic
information. In the present study mediastinal involvement
and size are found to be closely related to tumour burden
and to give no independent prognostic information.
Age has by others been found to be of prognostic
significance in relation to Hodgkin's disease in general,
especially in patients over the age of 50 (Wedelin et al.,
1984). In the present study age has no prognostic
significance with regard to disease free survival, which may,
however, be related to the fact that the large majority of
patients are under 50 years of age.
The only factors of prognostic importance apart from
tumour burden remaining after multivariate analysis are
histologic subtype and sex.
As a result of modern therapeutic advances histologic
subtype has in many studies in recent years shown a
diminishing influence on prognosis in the sense that the
difference in prognosis between NS and MC has been
virtually eliminated in early stage disease (Kaplan, 1980a). In
the present study histologic subtype is a significant
prognostic factor with LP having the best and MC the
poorest disease free survival. NS has an intermediate disease
free survival which in the final multivariate model is,
however, neither significantly different from LP nor from
MC.
Sex has a small but significant impact on disease free
survival, which is in accordance with many earlier studies
(Tubiana et al., 1985; Kaplan, 1980b).
The combination of tumour burden and histologic
subtype, the 2 factors with the greatest independent
prognostic significance, makes it possible to single out more
accurately than by any other prognostic factors a group of
patients with a very poor disease free survival. These
patients, comprising about 1/3 of the total number, also have
a poor survival from Hodgkin's disease compared to the rest
of the patients and are obviously candidates for additional
initial treatment.
The results of the present study indicate that for the early
stages of Hodgkin's disease, tumour burden assessed by the
fairly simple method proposed above based on physical
examination and ordinary chest radiographs is the single
most important prognostic factor with regard to disease free
survival after radiotherapy. Virtually all the hitherto known
important prognostic factors are closely related to tumour
burden and, hence, are of no independent prognostic
significance. The combination of tumour burden and
histologic subtype singles out patients destined to relapse
after radiotherapy alone more accurately than any other
known prognostic factor or combination of factors.
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